Clinical trial
Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
NCT07225361
Study timeline
Study start (actual)2025-11-28Date precision: day
Registry last updated2026-03-17
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Multiple Sclerosisunresolved
Interventions
UblituximabDRUG · verified · RxNorm: ublituximab
Sponsors & collaborators
Northwestern Universitylead sponsor
TG Therapeutics, Inc.collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT07225361 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.